Listed times are in Central European Time (CET)

WELCOME TO DAY ONE

Chair: Rene Bernards

Matheus Dias NKI, Netherlands

'Therapeutic OVERactivation of oncogenic signalling as a cancer treatment strategy'

Q&A: 12:25-12:35

Vesselina Cooke Novartis, USA

'Small Molecule-induced ERK Hyperactivation as a Novel Therapeutic Approach for BRAF V600-Mutant Melanoma'

Q&A: 12:55-13:05

Proffered Paper 1

Q&A: 13:15-13:20

Proffered Paper 2

Q&A: 13:30-13:35

REFRESHMENT BREAK

Chair: Bart Vanhaesebroeck

FLASH TALKS 1

A selection of high-scoring abstracts presented as 3 minute flash talks.

Arun Unni Weill Cornell Medicine, USA

'Understanding the consequences of excess RAS pathway activity in cancer cells'

Q&A: 14:25-14:35

Proffered Paper 3

Q&A: 14:45-14:50

REFRESHMENT BREAK

FLASH TALKS 2

A selection of high-scoring abstracts presented as 3 minute flash talks.

Proffered Paper 4

Q&A: 15:30-15:35

Proffered Paper 5

Q&A: 15:45-15:50

Closing Keynote

Markus Muschen Yale School of Medicine, USA

'Targeted hyperactivation of oncogenic BCR-signaling in refractory B-cell malignancies'

Q&A: 16:15-16:30

SUMMARY AND CLOSE

Listed times are in Central European Time (CET)

WELCOME TO DAY TWO

Chair: Bart Vanhaesebroeck

Benoit Bilanges UCL Cancer Institute, UK

'Induction of cancer cell death by direct pharmacological PI3Kα activation under stress conditions: a proof-of-concept'

Q&A: 12:25-12:35

Eunice Cho The Broad Institute, USA

'Directed clonal evolution: Leveraging divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation'

Q&A: 12:55-13:05

Proffered Paper 6

Q&A: 13:15-13:20

Proffered Paper 7

Q&A: 13:30-13:35

REFRESHMENT BREAK

FLASH TALKS 3

A selection of high-scoring abstracts presented as 3 minute flash talks.

Proffered Paper 8

Q&A: 14:15-14:20

Andrew Intlekofer MSKCC, USA

'Enzyme hyperactivation to target oncometabolism'

Q&A: 14:40-14:50

REFRESHMENT BREAK

Chair: Rene Bernards

FLASH TALKS 4

A selection of high-scoring abstracts presented as 3 minute flash talks.

Kimberly Stegmaier Dana-Farber Cancer Institute, USA

'EWS::FLI1 Activation Lethality in Ewing Sarcoma'

Q&A: 15:40-15:50

Proffered Paper 9

Q&A 16:00-16:05

DISCUSSION SESSION

CONFERENCE SUMMARY AND CLOSE